检查点抑制剂时代霍奇金淋巴瘤异基因造血干细胞移植的结局:CIBMTR与EBMT联合分析
该研究纳入2008至2023年接受首次异基因造血干细胞移植的2186例成人霍奇金淋巴瘤患者,27%有检查点抑制剂暴露史。多变量分析显示,既往检查点抑制剂暴露不影响总生存或非复发死亡,但改善无进展生存并降低复发率,同时增加2至4级和3至4级急性移植物抗宿主病,慢性移植物抗宿主病差异无统计学意义。
要点
- 既往检查点抑制剂暴露不影响异基因移植后总生存或非复发死亡。
- 既往检查点抑制剂暴露改善无进展生存并降低复发率。
- 既往检查点抑制剂暴露增加2至4级和3至4级急性移植物抗宿主病,慢性移植物抗宿主病无显著差异。
核心结论
- 在检查点抑制剂时代,异基因造血干细胞移植仍应被视为霍奇金淋巴瘤患者的治愈性选择。
研究设计与样本
- 国际血液与骨髓移植研究中心(CIBMTR)与欧洲血液与骨髓移植学会(EBMT)联合研究,纳入2008至2023年接受首次异基因造血干细胞移植的2186例年龄>18岁成人患者,供者类型为相合同胞、无关或单倍体。
- 27%的患者有既往检查点抑制剂暴露史。
- 移植物抗宿主病预防方案为移植后环磷酰胺(PTCy)者在检查点抑制剂队列占55.8%,在非检查点抑制剂队列占35%。
主要发现
- 多变量分析中,既往检查点抑制剂暴露不影响总生存或非复发死亡。
- 慢性移植物抗宿主病差异无统计学意义。
临床怎么用
- 在检查点抑制剂时代,异基因造血干细胞移植仍应被视为霍奇金淋巴瘤患者的治愈性选择。
- 在既往检查点抑制剂暴露患者中,基于PTCy的移植物抗宿主病预防方案改善总生存、降低2至4级急性移植物抗宿主病和慢性移植物抗宿主病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Checkpoint inhibitors (CPIs) have shown remarkable efficacy in Hodgkin lymphoma (HL), and are now used routinely. While allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative option for HL, there are concerns prior CPIs may exacerbate post-allo-HCT complications, particularly graft-versus-host disease (GVHD), and lead to worse outcomes. Given the relative paucity of data, we performed a Center for International Blood and Marrow Transplant Research/European Society for Blood and Marrow Transplantation study to examine the impact of prior CPIs in allo-HCT. We included 2186 adult patients aged >18 years who received a first allo-HCT using a matched related, unrelated, or haploidentical donor from 2008 to 2023. Twenty-seven percent of patients received prior CPIs. GVHD prophylaxis was posttransplant cyclophosphamide (PTCy) in 55.8% of patients in the CPI cohort, and 35% in the non-CPI cohort. Median follow-up among survivors was longer for the non-CPI (39 months) than CPI cohort (16.5 months). In multivariate analysis, prior CPI exposure did not affect overall survival (OS) or nonrelapse mortality, but resulted in improved progression-free survival (non-CPI vs CPI hazard ratio [HR], 0.81; 0.67-0.98; P = .03) and lower relapse incidence (HR, 0.58; 0.45-0.76; P < 001). While grade 2 to 4 (HR, 1.26; 1.04-1.53; P = .02) and 3 to 4 (HR, 1.41; 1.04-1.92; P = .03) acute GVHD (aGVHD) were increased, differences in chronic GVHD (cGVHD) were not significant. PTCy-based GVHD prophylaxis resulted in improved OS, lower grade 2 to 4 aGVHD, and cGVHD in patients with prior CPI exposure. In summary, allo-HCT should still be considered a curative option for patients with HL in the era of CPIs.
引用
- Perales MA, Awan FT, Boumendil A, et al. Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis. Blood. 2025. PMID: 40623049. doi:10.1182/blood.2024027197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。